<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02988531</url>
  </required_header>
  <id_info>
    <org_study_id>AC16105</org_study_id>
    <nct_id>NCT02988531</nct_id>
  </id_info>
  <brief_title>Validation of PET-MRI for Cardiovascular Disease</brief_title>
  <official_title>Validation of PET-MRI for Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether PET-MRI can obtain comparable images to PET-CT in those with coronary&#xD;
      artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron emission tomography (PET) is method of non-invasively imaging a metabolic process.&#xD;
      It has been used in clinical medicine for many years with its primary use in identifying&#xD;
      areas of increased metabolic activity as possible cancers. It involves the use of a&#xD;
      radionuclide (or radiotracer) labelled to a chemical involved in a certain metabolic process.&#xD;
      In order for the PET signal from the radiotracer to be detected by the scanner the&#xD;
      radionuclide emits a small dose of ionizing radiation. Examples of commonly used&#xD;
      radionuclides include 18FDG and 18 Sodium Fluoride (18NaF). In order to locate where exactly&#xD;
      these areas of abnormal or increased metabolic activity were, Computerised Tomography (CT)&#xD;
      has traditionally been used for anatomical correlation.&#xD;
&#xD;
      Until recently PET-CT has largely been confined for use in oncology. More recently however&#xD;
      PET-CT has been utilized to detect vulnerable plaques in those with coronary artery disease.&#xD;
      In coronary artery disease 18F-fluoride acts as a marker of novel calcification activity&#xD;
      within the plaque. Similar to other conditions, calcification in coronary atheroma occurs as&#xD;
      a healing response to intense necrotic inflammation, making 18F- fluoride a useful marker of&#xD;
      high-risk atherosclerotic plaque. This has been demonstrated in those with stable angina as&#xD;
      well as localizing the culprit plaque in those with myocardial infarction in 90% of cases.&#xD;
&#xD;
      Magnetic resonance imaging is being increasingly adopted in cardiovascular imaging and holds&#xD;
      particular attraction due to its ability to provide information about soft tissue structures&#xD;
      both with and without contrast agents, as well as its safety due to absence of exposure to&#xD;
      ionising radiation and rapid imaging speed, which is useful in a moving organ like the heart.&#xD;
&#xD;
      PET-MR works differently to PET-CT. PET relies on the annihilation of protons with electrons,&#xD;
      generating 511 keV photons, which are absorbed in bodily tissues differently depending on&#xD;
      their electron density (e.g. heart denser than lungs). Because of this PET images can appear&#xD;
      brighter or darker in different tissues. To account for this, a technique of attenuation&#xD;
      correction is employed. This is usually in the form of what is called a transmission scan&#xD;
      (low intensity CT scan) which grades tissue density and corrects the PET signal accordingly.&#xD;
      Given MRI measures proton density and not electron density different attenuation correction&#xD;
      techniques are needed. It has not yet been established how best to do this despite multiple&#xD;
      efforts using differing techniques.&#xD;
&#xD;
      Previous single centre studies have demonstrated the feasibility of MRI-PET. The technique's&#xD;
      translation to clinical practice has been limited due to the global lack of reliable&#xD;
      attenuation correction methods. During his recent Clinical Research Imaging Fellowship in New&#xD;
      York, co-investigator (Dr Dweck) developed a novel free breathing method of attenuation&#xD;
      correction in a combined PET-MR scanner that reduced scanning time and improved efficiency&#xD;
      and has shown immense promise. In Edinburgh a similar combined PET-MR scanner (mMR, Siemens,&#xD;
      Erlangen, Germany) has been installed, but have not yet replicated or validated this&#xD;
      technique. If the investigators can demonstrate and apply a method of attenuation correction&#xD;
      that is acceptable and shows good comparability of MRI-PET to PET-CT images they may be able&#xD;
      to use this imaging method as an alternative to PET-CT.&#xD;
&#xD;
      Benefits which may translate clinically include superior soft tissue characterisation and&#xD;
      significantly reduced radiation dosages. The technique could be applied across a range of&#xD;
      medical conditions in addition to cardiovascular disease and oncology.&#xD;
&#xD;
      The investigators are hopeful to establish a suitable attenuation correction method so that&#xD;
      PET-MR can match or even supersede PET-CT as an imaging technique providing accurate&#xD;
      biological, anatomical and functional information in those with cardiovascular disease with&#xD;
      low radiation doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Actual">December 7, 2017</completion_date>
  <primary_completion_date type="Actual">December 7, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The standard uptake values (SUV's) of volumes of interest (VOI's) on corresponding PET-CT and PET-MR images will be evaluated by expert. The distribution of PET positive VOI's will be compared using a cut-off of 1.6 for tissue to background ratio (TBR).</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard breath-held MR-based attenuation correction will be compared to a novel free-breathing approach. Impact on PET image artifacts and the interpretation of vascular uptake will be evaluated semi-quantitatively by expert readers.</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>MRI</condition>
  <condition>PET Scan</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to have PET/MR scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/MR scan</intervention_name>
    <description>Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.</description>
    <arm_group_label>PET/MR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing thoracic PET-CT scans (this can include NHS and patients enrolled&#xD;
             in other research studies)&#xD;
&#xD;
          -  Aged over 50 years old. No upper age limit&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwilling to give informed consent.&#xD;
&#xD;
          -  Major intercurrent illness with life-expectancy &lt;2 years.&#xD;
&#xD;
          -  Contra-indication to Magnetic resonance imaging.&#xD;
&#xD;
          -  Permanent or persistent atrial fibrillation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48. doi: 10.1016/j.jacc.2011.12.037.</citation>
    <PMID>22516444</PMID>
  </reference>
  <reference>
    <citation>Dweck MR, Khaw HJ, Sng GK, Luo EL, Baird A, Williams MC, Makiello P, Mirsadraee S, Joshi NV, van Beek EJ, Boon NA, Rudd JH, Newby DE. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J. 2013 Jun;34(21):1567-74. doi: 10.1093/eurheartj/eht034. Epub 2013 Feb 7.</citation>
    <PMID>23391586</PMID>
  </reference>
  <reference>
    <citation>Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014 Feb 22;383(9918):705-13. doi: 10.1016/S0140-6736(13)61754-7. Epub 2013 Nov 11.</citation>
    <PMID>24224999</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 23, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <keyword>Attenuation</keyword>
  <keyword>Correction</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>coronary</keyword>
  <keyword>disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share patient specific data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02988531
org study id: AC16105
nct id: NCT02988531
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
To determine whether PET-MRI can obtain comparable images to PET-CT in those with coronary
      artery disease.
Positron emission tomography (PET) is method of non-invasively imaging a metabolic process.
      It has been used in clinical medicine for many years with its primary use in identifying
      areas of increased metabolic activity as possible cancers. It involves the use of a
      radionuclide (or radiotracer) labelled to a chemical involved in a certain metabolic process.
      In order for the PET signal from the radiotracer to be detected by the scanner the
      radionuclide emits a small dose of ionizing radiation. Examples of commonly used
      radionuclides include 18FDG and 18 Sodium Fluoride (18NaF). In order to locate where exactly
      these areas of abnormal or increased metabolic activity were, Computerised Tomography (CT)
      has traditionally been used for anatomical correlation.

      Until recently PET-CT has largely been confined for use in oncology. More recently however
      PET-CT has been utilized to detect vulnerable plaques in those with coronary artery disease.
      In coronary artery disease 18F-fluoride acts as a marker of novel calcification activity
      within the plaque. Similar to other conditions, calcification in coronary atheroma occurs as
      a healing response to intense necrotic inflammation, making 18F- fluoride a useful marker of
      high-risk atherosclerotic plaque. This has been demonstrated in those with stable angina as
      well as localizing the culprit plaque in those with myocardial infarction in 90% of cases.

      Magnetic resonance imaging is being increasingly adopted in cardiovascular imaging and holds
      particular attraction due to its ability to provide information about soft tissue structures
      both with and without contrast agents, as well as its safety due to absence of exposure to
      ionising radiation and rapid imaging speed, which is useful in a moving organ like the heart.

      PET-MR works differently to PET-CT. PET relies on the annihilation of protons with electrons,
      generating 511 keV photons, which are absorbed in bodily tissues differently depending on
      their electron density (e.g. heart denser than lungs). Because of this PET images can appear
      brighter or darker in different tissues. To account for this, a technique of attenuation
      correction is employed. This is usually in the form of what is called a transmission scan
      (low intensity CT scan) which grades tissue density and corrects the PET signal accordingly.
      Given MRI measures proton density and not electron density different attenuation correction
      techniques are needed. It has not yet been established how best to do this despite multiple
      efforts using differing techniques.

      Previous single centre studies have demonstrated the feasibility of MRI-PET. The technique's
      translation to clinical practice has been limited due to the global lack of reliable
      attenuation correction methods. During his recent Clinical Research Imaging Fellowship in New
      York, co-investigator (Dr Dweck) developed a novel free breathing method of attenuation
      correction in a combined PET-MR scanner that reduced scanning time and improved efficiency
      and has shown immense promise. In Edinburgh a similar combined PET-MR scanner (mMR, Siemens,
      Erlangen, Germany) has been installed, but have not yet replicated or validated this
      technique. If the investigators can demonstrate and apply a method of attenuation correction
      that is acceptable and shows good comparability of MRI-PET to PET-CT images they may be able
      to use this imaging method as an alternative to PET-CT.

      Benefits which may translate clinically include superior soft tissue characterisation and
      significantly reduced radiation dosages. The technique could be applied across a range of
      medical conditions in addition to cardiovascular disease and oncology.

      The investigators are hopeful to establish a suitable attenuation correction method so that
      PET-MR can match or even supersede PET-CT as an imaging technique providing accurate
      biological, anatomical and functional information in those with cardiovascular disease with
      low radiation doses.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Diagnostic
masking: None (Open Label)
measure: The standard uptake values (SUV's) of volumes of interest (VOI's) on corresponding PET-CT and PET-MR images will be evaluated by expert. The distribution of PET positive VOI's will be compared using a cut-off of 1.6 for tissue to background ratio (TBR).
time frame: 7 months
measure: Standard breath-held MR-based attenuation correction will be compared to a novel free-breathing approach. Impact on PET image artifacts and the interpretation of vascular uptake will be evaluated semi-quantitatively by expert readers.
time frame: 7 months
arm group label: PET/MR
arm group type: Experimental
description: Participants to have PET/MR scan
intervention type: Other
intervention name: PET/MR scan
description: Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
arm group label: PET/MR
criteria: 
gender: All
minimum age: 50 Years
maximum age: N/A
healthy volunteers: No
facility: 
country: United Kingdom
citation: Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48. doi: 10.1016/j.jacc.2011.12.037.
PMID: 22516444
citation: Dweck MR, Khaw HJ, Sng GK, Luo EL, Baird A, Williams MC, Makiello P, Mirsadraee S, Joshi NV, van Beek EJ, Boon NA, Rudd JH, Newby DE. Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J. 2013 Jun;34(21):1567-74. doi: 10.1093/eurheartj/eht034. Epub 2013 Feb 7.
PMID: 23391586
citation: Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014 Feb 22;383(9918):705-13. doi: 10.1016/S0140-6736(13)61754-7. Epub 2013 Nov 11.
PMID: 24224999
responsible party type: Sponsor
mesh term: Cardiovascular Diseases
mesh term: Coronary Artery Disease
sharing ipd: No
ipd description: No plans to share patient specific data